BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1012 related articles for article (PubMed ID: 1954724)

  • 1. Contraception for women with diabetes: an update.
    Skouby SO; Mølsted-Pedersen L; Petersen KR
    Baillieres Clin Obstet Gynaecol; 1991 Jun; 5(2):493-503. PubMed ID: 1954724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles.
    Skouby SO; Mølsted-Pedersen L; Kühl C; Bennet P
    Fertil Steril; 1986 Nov; 46(5):858-64. PubMed ID: 3781003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose and lipid metabolism with triphasic oral contraceptives in women with history of gestational diabetes.
    Kung AW; Ma JT; Wong VC; Li DF; Ng MM; Wang CC; Lam KS; Young RT; Ma HK
    Contraception; 1987 Mar; 35(3):257-69. PubMed ID: 3111786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid and biochemical changes after low-dose oral contraception.
    Loke DF; Ng CS; Holck S; Hall PE; Ratnam SS
    Contraception; 1992 Sep; 46(3):227-41. PubMed ID: 1451519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism.
    Loke DF; Ng CS; Samsioe G; Holck S; Ratnam SS
    Contraception; 1990 Nov; 42(5):535-54. PubMed ID: 2125546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN; Liew D; Ratnam SS
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
    Lachnit-Fixson U
    Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contraception in the diabetic woman.
    Kjos SL
    Clin Perinatol; 1993 Sep; 20(3):649-61. PubMed ID: 8222475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
    Spellacy WN
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception.
    Contraception; 1980 May; 21(5):445-59. PubMed ID: 7428356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
    Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.